Featuring perspectives from Dr Komal Jhaveri,
Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy, Dr Hope S
Rugo and Prof Peter Schmid, including the following topics:
Long-Term Management of
HER2-Positive Breast Cancer
Introduction (0:00)
Management of CNS-only
disease progression in patients with HER2-positive metastatic
breast cancer (2:27)
Synergy between tucatinib
and HER2-targeted antibody-drug conjugates (5:24)
Management of trastuzumab
deruxtecan–related adverse events (7:41)
Patient selection for and
practical implementation of postadjuvant neratinib (13:23)
Faculty presentation: Dr
Krop (16:26)
Optimizing the Management of
ER-Positive Localized Breast Cancer
Ovarian function suppression
to preserve fertility and prevent premature ovarian insufficiency;
interrupting adjuvant hormonal therapy to attempt pregnancy
(24:56)
Selection of patients for
adjuvant tamoxifen monotherapy (29:05)
Utility of genomic assays in
the neoadjuvant setting; management of node-positive disease in
postmenopausal patients with low-risk Recurrence Scores®
(33:35)
Selection between
abemaciclib and ribociclib in the adjuvant setting (36:45)
Potential utility of
circulating tumor DNA assessment in breast cancer (41:58)
Faculty presentation: Dr
Kalinsky (46:36)
Considerations in the Care
of Patients with ER-Positive Metastatic Breast Cancer
Preference of CDK4/6
inhibitor in the metastatic setting (56:42)
Sequencing of trastuzumab
deruxtecan in ER-positive, HER2-low metastatic breast cancer
(59:00)
Faculty presentation: Dr
Jhaveri (1:06:39)
Novel and Emerging
Strategies for ER-Positive Metastatic Breast Cancer
Selection of therapy for
ER-positive metastatic breast cancer progressing on a CDK4/6
inhibitor; future role of capivasertib (1:19:31)
Faculty presentation: Dr
Rugo (1:30:39)
Evolving Clinical
Decision-Making for Localized Triple-Negative Breast Cancer (TNBC)
Management of localized
TNBC; selection of patients for adjuvant Olaparib (1:46:10)
PARP inhibitor tolerability
(1:51:55)
Faculty presentation: Dr
O’Shaughnessy (1:55:31)
Recent Advances in the
Treatment of Metastatic TNBC (mTNBC)
Selection of therapy for
triple-negative metastatic breast cancer; sequencing of trastuzumab
deruxtecan in ER-negative, HER2-low disease (2:11:08)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.